HOME
The Info List - Increlex



Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is recombinant form of human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[1][2]

A related drug is mecasermin rinfabate (trade name Iplex), which is a combination of rhIGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.

References

  1. ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186Freely accessible. PMID 19707272. 
  2. ^ "Increlex". Drugs.com. Retrieved 10 January 2010. 




Warning: Invalid argument supplied for foreach() in D:\Bitnami\wampstack-7.1.16-0\apache2\htdocs\php\PeriodicService.php on line 61